Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Fluoxetine (Reconcile) for Canine Behavior Disorders
Clinical reference on fluoxetine (Reconcile/Prozac) for dogs: FDA-approved separation-anxiety indication, 1-2 mg/kg dosing, 4-6 week onset, adverse effects, and the MAOI/amitraz and serotonin-syndrome interactions every prescriber must screen for.
Read →Methylxanthine (Chocolate & Caffeine) Toxicosis in Dogs
ER reference for canine methylxanthine (chocolate/caffeine) toxicosis: theobromine/caffeine MOA and kinetics, mg/kg dose thresholds, chocolate-type ranking, decontamination, and symptomatic management of tachyarrhythmia, seizures, and hyperthermia.
Read →Grape & Raisin Nephrotoxicosis in Dogs: AKI Management
Clinical reference on grape, raisin, and tamarind nephrotoxicosis in dogs: the idiosyncratic (no safe-dose) nature, the 2022 tartaric-acid hypothesis, the biphasic GI-then-AKI timeline, decontamination, fluid diuresis with serial renal-value monitoring, and prognosis by oliguric status.
Read →Anticoagulant Rodenticide Toxicosis in Dogs: Clinical Management
A DVM's clinical reference for anticoagulant rodenticide toxicosis in dogs: mechanism, delayed 3-5 day presentation, PT as the earliest marker, vitamin K1 antidotal dosing and duration by generation, plasma for active bleeding, and the recheck-PT-after-stopping rule.
Read →Xylitol Toxicosis in Dogs: Clinical Management
A DVM reference for xylitol toxicosis in dogs: hypoglycemia at ~0.1 g/kg and hepatic necrosis at ~0.5 g/kg, delayed onset, why activated charcoal fails, and dextrose plus hepatoprotectant protocols with monitoring intervals and prognosis.
Read →Sago Palm (Cycad) Hepatotoxicosis in Dogs: Clinical Management
A clinical reference for managing sago palm (Cycas revoluta) toxicosis in dogs: cycasin/MAM mechanism, the three-phase course, decontamination with multi-dose activated charcoal, hepatoprotectant dosing (NAC, SAMe, silymarin), coagulopathy management, monitoring, and prognosis.
Read →Cannabis (THC) Toxicosis in Dogs: Emergency Management
A point-of-care clinical reference for THC toxicosis in dogs: toxicokinetics, the neurologic hallmark, decontamination criteria, supportive care and intravenous lipid emulsion dosing, the edible co-toxin trap, and prognosis.
Read →Ilunocitinib (Zenrelia): A Clinical Guide to the Once-Daily JAK Inhibitor for Canine Atopic Dermatitis
Ilunocitinib (Zenrelia, Elanco) is a once-daily oral JAK inhibitor for canine allergic and atopic dermatitis. This hub covers mechanism, dosing, the head-to-head data versus oclacitinib, the boxed vaccination warning, and where it fits alongside Apoquel, Cytopoint, and ciclosporin.
Read →Canine SCCED (Indolent Corneal Ulcers): Debridement and Outcomes
A practical clinical hub on spontaneous chronic corneal epithelial defects in dogs: how to diagnose an indolent ulcer, the mechanical debridement ladder from cotton-tip to diamond burr to grid keratotomy to superficial keratectomy, comparative single-procedure healing rates, bandage lens and serum adjuncts, and when to escalate.
Read →Canine Keratoconjunctivitis Sicca (KCS): Diagnosis and Treatment
A practical clinical hub on canine keratoconjunctivitis sicca: Schirmer tear test diagnosis and severity thresholds, topical calcineurin inhibitors (ciclosporin, tacrolimus) as first-line, tear replacement, oral pilocarpine for neurogenic KCS, parotid duct transposition for refractory cases, and where injectable PRP plus oral omega-3 fit as adjuncts.
Read →Canine Primary Glaucoma: Diagnosis and Management
A practical clinical reference on canine primary glaucoma: pathophysiology and goniodysgenesis, tonometry and gonioscopy, emergency IOP-lowering protocols, maintenance medical therapy, surgical options for sighted and blind eyes, and evidence-based fellow-eye prophylaxis.
Read →Canine Dilated Cardiomyopathy: Hereditary DCM, Diet-Associated DCM, Preclinical Screening, and Evidence-Based Management
DCM affects up to 58% of Dobermans; annual Holter screening recommended from age 3. FDA grain-free/DCM investigation closed Dec 2022 without confirmed caus
Read →